Tonix Pharmaceuticals, Set To File An NDA For Tonmya For The Management Of Fibromyalgia, Assuming Approval By The FDA In 2H 2025
Portfolio Pulse from Benzinga Newsdesk
Tonix Pharmaceuticals (NASDAQ:TNXP) is set to file an NDA for Tonmya for fibromyalgia management in 2H 2024, with potential FDA approval in 2H 2025. This could mark the first new FDA-approved fibromyalgia drug in over 15 years, potentially sparking a market rivalry.
July 17, 2024 | 12:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Tonix Pharmaceuticals is preparing to file an NDA for Tonmya in 2H 2024, with potential FDA approval in 2H 2025. This could be the first new FDA-approved fibromyalgia drug in over 15 years, potentially revitalizing the market.
The news of filing an NDA and potential FDA approval for Tonmya is significant for Tonix Pharmaceuticals. If approved, it would be the first new fibromyalgia drug in over 15 years, likely boosting TNXP's stock price due to the potential market impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100